Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

GIST management is driven by mutation type, not just tumour size. This guide sets out the molecular workup, the combined clinical-molecular risk stratification, and how imatinib, sunitinib, regorafenib and ripretinib are sequenced.

What this guide covers: Presentation · Diagnosis · Molecular testing is now mandatory · Risk stratification · Surgery

Gastrointestinal stromal tumour is the commonest mesenchymal tumour of the digestive tract, arising from the interstitial cells of Cajal or their precursors. It is also the model disease for molecularly driven cancer treatment: the choice and dose of therapy depends on which mutation the tumour carries.

GIST accounts for roughly 1 to 3 percent of gastrointestinal tumours, with an annual incidence of about 1.1 to 1.5 per 100,000. Median age at diagnosis is around 60. The stomach accounts for 50 to 60 percent and the small intestine 30 to 35 percent; colorectum, oesophagus and extra-gastrointestinal sites are less common.

Presentation

Between 20 and 30 percent of GISTs are found incidentally. When symptomatic, patients present with abdominal pain, a sense of fullness, gastrointestinal bleeding — which may be overt or present as iron-deficiency anaemia — or, less often, obstruction or a palpable mass. The liver is the dominant site of metastasis, followed by peritoneal seeding.

Diagnosis

Endoscopy shows a submucosal bulge with intact or ulcerated mucosa. Endoscopic ultrasound is the key test for characterising the lesion and, for small gastric lesions, for deciding whether observation is safe.

Contrast-enhanced CT of the abdomen is the standard staging investigation; GISTs are typically hypervascular with brisk arterial enhancement. MRI is more sensitive for liver metastases. PET-CT is valuable for assessing metabolic response to targeted therapy, where shrinking may lag behind biological response.

Histologically GIST is spindle cell in about 70 percent of cases, epithelioid in 20 percent, and mixed in the remainder. Immunohistochemistry is the cornerstone: CD117 is positive in over 90 percent and DOG-1 in around 95 to 98 percent, and using both together raises diagnostic accuracy above 98 percent.

Molecular testing is now mandatory

All patients with a new or recurrent GIST should have mutational analysis. Testing covers KIT exons 9, 11, 13 and 17 and PDGFRA exons 12, 14 and 18, extended to SDH complex genes, NTRK fusions and rarer drivers including BRAF and KRAS. Next-generation sequencing panels are preferred because they capture the full set at once, and circulating tumour DNA is increasingly used to track clonal evolution and resistance during treatment.

Roughly 5 percent of GISTs are wild-type for KIT and PDGFRA. SDH-deficient GIST — identifiable by loss of SDHB staining — occurs in children, young adults and Carney triad patients and behaves differently.

Risk stratification

The modified NIH classification combines tumour size, mitotic count, site and rupture. The 2025 approach adds molecular features as modifiers: KIT exon 11 deletions, particularly involving codons 557 to 558, behave aggressively; PDGFRA D842V is imatinib-resistant but often indolent; SDH-deficient tumours metastasise early, often to liver. A gastric tumour of 5 cm with five mitoses per 50 high-power fields would be intermediate risk on pathology alone but is upgraded to high risk when a KIT exon 11 deletion is present — and that changes the adjuvant recommendation.

Surgery

Complete resection with an intact pseudocapsule is the goal, because tumour rupture multiplies recurrence risk several-fold. Gastric lesions up to 2 cm without high-risk endoscopic features may be observed with imaging every 6 to 12 months, particularly in older or comorbid patients; lesions above 2 cm, or any with concerning features, are resected. Laparoscopy is suitable for larger gastric and small bowel lesions without rupture risk when a retrieval bag is used. Endoscopic resection is not recommended where malignant potential is high, because margin control is inferior.

Systemic therapy

Imatinib 400 mg daily is standard first-line for KIT or PDGFRA mutant disease. Patients with KIT exon 9 mutations do better with 800 mg daily. PDGFRA D842V is resistant to imatinib and is treated with avapritinib. SDH-deficient GIST responds poorly to imatinib and is best managed in a trial. NTRK fusion-positive tumours respond to entrectinib or larotrectinib.

After progression on imatinib, sunitinib is standard second-line, and the choice beyond that depends on the resistance mutation: KIT exon 13 or 14 secondary mutations tend to remain sunitinib-sensitive, whereas exon 17 or 18 mutations are not, and ripretinib may be preferred. Regorafenib is the established third-line agent, with ripretinib as fourth-line.

Adjuvant therapy

High-risk patients benefit from three years of adjuvant imatinib, and selected very high-risk patients — tumour rupture, high mitotic rate, KIT exon 11 deletion — from five years. Low-risk patients do not benefit. Dose reduction for toxicity preserves efficacy in most cases.

Follow-up

Surveillance is by contrast CT at intervals determined by risk, typically every three to six months in the first years for high-risk disease. Because late recurrence occurs, follow-up continues for years, and any new lesion in a treated patient should prompt reassessment of the molecular profile rather than a blind change of drug.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.